IL6 and non-small cell lung carcinoma: Clinical findings demonstrated that levels of IL-6 increased in the circulation and regional fluids were associated with poor prognosis of patients with malignant diseases (Uskudar Teke et al. 2015), and the antibody against IL-6 siltuximab could inhibit the phosphorylation of STAT3 tyrosine and cell growth in NSCLC (Song et al. 2011).